EGI
COGT icon

EAM Global Investors’s Cogent Biosciences COGT Stock Holding History

EAM Global Investors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-122,938
Closed -$1.83M – 187
2022
Q3 		$1.83M Sell
122,938
-58,643
-32% -$804K 0.49% 89
2022
Q2 		$1.64M Buy
+181,581
New +$1.24M 0.4% 118

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

EAM Global Investors's COGT Position: Q4 2022 in Review

EAM Global Investors sold out of Cogent Biosciences (COGT) in Q4 2022, closing a stake of 122,938 shares — an estimated $1.83M sold.

EAM Global Investors first reported a position in COGT in Q2 2022 and held it in 2 quarters. The position peaked at $1.83M in Q3 2022. 135 funds tracked by Wall St. Rank hold COGT as of Q4 2022.

  • EAM Global Investors reported no remaining Cogent Biosciences position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 122,938 Cogent Biosciences shares in Q4 2022, an estimated $1.83M.
  • EAM Global Investors first reported a position in Cogent Biosciences in Q2 2022 and held it in 2 quarters.
  • EAM Global Investors's Cogent Biosciences position peaked at $1.83M in Q3 2022.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.